ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report

被引：11
|
作者：
Ou, Kai [1 ]
Liu, Xiu [1 ]
Li, Weihua [2 ]
Yang, Yi [3 ]
Ying, Jianming [2 ,4 ]
Yang, Lin [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Pathol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Intervent Therapy, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Gene Editing Screening & Res & Dev R&D Di, Beijing, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词：
pancreatic cancer; brain metastases; ALK Kinase; EML4-ALK fusion protein; crizotinib; alectinib; CSF CONCENTRATION; IDENTIFICATION; FUSION; CRIZOTINIB; CHEMOTHERAPY; EXPRESSION; CARCINOMA; SURVIVAL; TUMORS; GENE;
D O I：
10.3389/fonc.2021.724815
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with metastatic pancreatic cancer typically have poor prognosis due to the limited effectiveness of existing treatment options. ALK rearrangement-positive is rare in pancreatic cancer, but may occur in those with KRAS-wild type. We present a 34-year-old young man with ALK rearrangement-positive and KRAS-wild pancreatic cancer who had a remarkable response to crizotinib after resistance to prior chemotherapy and re-response to alectinib after brain metastases developed. This clinical observation suggests that comprehensive molecular profiling to guide targeted therapies is not only feasible, but also significantly improves survival outcomes for a subgroup of patients with pancreatic cancer.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
    Zhu, Lucheng
    Ma, Shenglin
    Xia, Bing
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [22] STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
    Feng, Chunlai
    Zhou, Rong
    Liu, Feng
    Wang, Tingting
    Liu, Sisi
    Shao, Yang
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [23] Ovarian Metastasis of ALK Translocation-Positive Lung Adenocarcinoma: A Case Report
    Gezer, Sener
    Cabuk, Devrim
    Aksoy, Lale
    Ozturk, Seda Duman
    Ozkara, Sevgiye Kacar
    Yucesoy, Izzet
    [J]. TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2020, 35 (04): : 475 - 478
  • [24] Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement
    Yanhua Bai
    Wei Sun
    Dongfeng Niu
    Xin Yang
    Xinting Diao
    Yang Yu
    Dongmei Lin
    [J]. Virchows Archiv, 2021, 479 : 1079 - 1083
  • [25] Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement
    Bai, Yanhua
    Sun, Wei
    Niu, Dongfeng
    Yang, Xin
    Diao, Xinting
    Yu, Yang
    Lin, Dongmei
    [J]. VIRCHOWS ARCHIV, 2021, 479 (06) : 1079 - 1083
  • [26] Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire
    Figueiredo, Ana
    Rodrigues, Ana
    Gaspar, Carina
    Felizardo, Margarida
    [J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (04) : 545 - 555
  • [27] Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
    Wang, Zhan
    Geng, Yan
    Yuan, Ling-Yan
    Wang, Miao-Miao
    Ye, Chen-Yang
    Sun, Li
    Dai, Wei-Ping
    Zang, Yuan-Sheng
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire
    Ana Figueiredo
    Ana Rodrigues
    Carina Gaspar
    Margarida Felizardo
    [J]. Drugs - Real World Outcomes, 2023, 10 : 545 - 555
  • [29] Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report
    Hu, Han
    Dai, Hui
    Ding, Liren
    [J]. TRANSLATIONAL CANCER RESEARCH, 2022, 11 (08) : 2967 - 2972
  • [30] Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report
    Kobayashi, Takayuki
    Uehara, Yuji
    Watanabe, Kageaki
    Hishima, Tsunekazu
    Hosomi, Yukio
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (07):
12345